Serum brain natriuretic peptide and C-reactive protein levels in adolescent with polycystic ovary syndrome

Deveer, Rüya; Engin-Üstün, Yaprak; Uysal, Sema; Su, Filiz Akın; Sarıaslan, Seval; Gülerman, Cavidan; Mollamahmutoğlu, Leyla

doi:10.3109/09513590.2011.650758

Cited by 10 publications

(9 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, five studies further matched PCOS and control groups in terms of B 12 and folate levels [ 7 , 14 , 22 , 25 , 35 ]. The selection of PCOS patients in seven studies [ 15 , 16 , 18 , 26 , 35 , 36 , 42 ] was according to NIH, and the other 27 studies [ 7 , 11 – 14 , 17 , 19 – 25 , 27 – 34 , 37 – 41 , 43 ] used the Rotterdam criteria. Three studies were assessed as “medium” quality [ 18 , 35 , 43 ] and the other 31 were all “high” quality studies according to NOS.…”

Section: Resultsmentioning

confidence: 99%

Association between High Serum Homocysteine Levels and Biochemical Characteristics in Women with Polycystic Ovarian Syndrome: A Systematic Review and Meta-Analysis

et al. 2016

View full text Add to dashboard Cite

BackgroundElevated homocysteine levels have been observed in previous studies of PCOS; however, the nature of the associations between high homocysteine levels and the biochemical characteristics of polycystic ovarian syndrome (PCOS)—such as obesity, insulin resistance (IR), and androgen levels—is still uncertain.MethodsA systematic search was conducted electronically up to December 28, 2015 using specific eligibility criteria. Standardized mean difference (SMD) and the corresponding 95% confidence intervals (95% CIs) were used as a measure of effect size.ResultsA total of 34 studies (with 1,718 cases and 1,399 controls) of homocysteine levels in PCOS were pooled in this meta-analysis. Significantly lower homocysteine levels were found in controls than in PCOS patients (SMD = 0.895, 95% CI = 0.643–1.146, P<0.001; I2 = 90.4% and P<0.001 for heterogeneity), regardless of the degree of obesity, IR, or androgen levels. Homocysteine levels in non-IR PCOS patients were significantly lower than those of PCOS patients with IR (SMD = 0.69, 95% CI = 0.37–1.01, P<0.01; I2 = 0% and P = 0.50 for heterogeneity). However, metformin treatment did not appear to cause any significant change in the homocysteine levels of PCOS patients (SMD = –0.17, 95% CI = –1.10–0.75, P = 0.71; I2 = 92% and P<0.01 for heterogeneity).ConclusionsHigh homocysteine levels in women with PCOS are not related to degree of obesity, IR, or androgen levels. Metformin treatment cannot decrease the homocysteine levels in PCOS patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Association between High Serum Homocysteine Levels and Biochemical Characteristics in Women with Polycystic Ovarian Syndrome: A Systematic Review and Meta-Analysis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Of these, 45 studies provided data on other inflammatory markers such as IL-6, TNF-α, adiponectin, etc., as summarised in Table 2. Mean ± SD CRP values were not provided in 22 studies [42,46,60,62,63,65,66,68,72,73,78,82,83,92,93,99,108,110,112,118,119,121]. Authors of these articles were contacted to provide the missing data, but no response was received despite several reminders.…”

Section: Included Studiesmentioning

confidence: 99%

The Role of Chronic Inflammation in Polycystic Ovarian Syndrome—A Systematic Review and Meta-Analysis

Aboeldalyl

James

Seyam

et al. 2021

IJMS

View full text Add to dashboard Cite

Although the current literature associates polycystic ovarian syndrome (PCOS) with chronic inflammation, the evidence for this link remains inconclusive and its causal nature remains unclear. The purpose of this systematic review was to assess the inflammatory status in PCOS women and to determine whether it is related to PCOS or to its associated adiposity. We searched electronic databases including PUBMED, EMBASE and MEDLINE, SCOPUS, DynaMed plus, TRIP, ScienceDirect and Cochrane Library, for studies investigating C-reactive protein (CRP) and other inflammatory makers in PCOS women versus healthy controls. Quality and risk of bias for selected studies were assessed using the modified Newcastle–Ottawa scale. CRP data were extracted and pooled using RevMan for calculation of the standardized mean difference (SMD) and 95% confidence interval (CI). Eighty-five eligible studies were included in the systematic review, of which 63 were included in the meta-analysis. Pooled analysis of the 63 studies revealed significantly higher circulating CRP in PCOS women (n = 4086) versus controls (n = 3120) (SMD 1.26, 95%CI, 0.99, 1.53). Sensitivity meta-analysis of 35 high quality studies including non-obese women showed significantly higher circulating CRP in PCOS women versus controls (SMD 1.80, 95%CI, 1.36, 2.25). In conclusion, circulating CRP is moderately elevated in PCOS women independent of obesity, which is indicative of low-grade chronic inflammation.

show abstract

“…22 Currently, BNP, which is a peptide hormone released from cardiomyocytes upon a mechanical stretch, has been recommended for clinical use. 21,23 It is processed by furin and its inactive N-terminal (NT) fragment is NT-proBNP. 23 An NTproBNP of 8.5 kDa is now successfully used as a marker for congestive heart failure.…”

Section: Introductionmentioning

confidence: 99%

“…21,23 It is processed by furin and its inactive N-terminal (NT) fragment is NT-proBNP. 23 An NTproBNP of 8.5 kDa is now successfully used as a marker for congestive heart failure. 24 NT-proBNP is released into the plasma predominantly from ventricular cardiomyocytes, particularly in patients with chronic cardiac diseases.…”

Section: Introductionmentioning

confidence: 99%

“…16,17 It is a more sensitive and specific biomarker of ventricular dys-function than the active BNP. 23 Indeed, recent studies have shown that assessment of the NT-proBNP concentration is useful in identifying cardiac disease. 21,25 Unfortunately, the area under the receiver operating characteristic (ROC) curve was below 70% and sensitivity and specificity values were below 80%.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Substance P and Neuropeptide Y as Potential Biomarkers for Diagnosis of Acute Myocardial Infarction in Korean Patients

Han¹,

Seo²,

Jung³

et al. 2014

Bulletin of the Korean Chemical Society

View full text Add to dashboard Cite

Substance P and neuropeptide Y were discovered as early diagnostic biomarkers of acute myocardial infarction in Korean patients and confirmed using enzyme-linked immunosorbent assay (ELISA). We screened 12 peptides from the sera of Korean acute myocardial infarction (AMI) patients and detected 3 peptides (neuropeptide Y, substance P, and N-terminal pro-B-type natriuretic peptide) to be elevated from patients' sera by liquid chromatography mass/mass spectrometry. The elevated concentration of 3 peptides was confirmed by ELISA. The screening results revealed the substance P, neuropeptide Y, and pro-B-type natriuretic peptide (47-76) concentrations were higher in patients' sera than in healthy controls. The sensitivity and specificity of substance P for AMI diagnostic marker were 80% and 83%, respectively, and those of neuropeptide Y were 87% and 90%, respectively compared to healthy controls. These results suggest that substance P and neuropeptide Y could be used as early diagnostic biomarkers in patients with AMI.

show abstract

Serum brain natriuretic peptide and C-reactive protein levels in adolescent with polycystic ovary syndrome

Cited by 10 publications

References 23 publications

Association between High Serum Homocysteine Levels and Biochemical Characteristics in Women with Polycystic Ovarian Syndrome: A Systematic Review and Meta-Analysis

Association between High Serum Homocysteine Levels and Biochemical Characteristics in Women with Polycystic Ovarian Syndrome: A Systematic Review and Meta-Analysis

The Role of Chronic Inflammation in Polycystic Ovarian Syndrome—A Systematic Review and Meta-Analysis

Substance P and Neuropeptide Y as Potential Biomarkers for Diagnosis of Acute Myocardial Infarction in Korean Patients

Contact Info

Product

Resources

About